Medic Now

medicnow.com

Medic Now is the UK's leading recruitment agency for ambulance professionals. We enable Paramedics, IHCD Technicians, Emergency Care Assistants and PTS attendants to work on a flexible, locum basis within the industry. We are partnered with several NHS and private organisations throughout the UK; offering a sophisticated staffing solution for our clients with qualified and compliant pre-hospital professional's.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AKERS BIOSCIENCES AND PREMAS BIOTECH ANNOUNCE PROGRESS IN ITS VACCINE DEVELOPMENT FOR COVID-19

PipelineReview | April 06, 2020

news image

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate. The clone development process has four primary steps including first, the design and synthesis of the genes; second, the selecti...

Read More

MEDICAL

INVEST ONTARIO SUPPORTS NEW BIOMANUFACTURING FACILITY IN HAMILTON

Invest Ontario | April 01, 2022

news image

Invest Ontario is supporting OmniaBio Inc. in launching a new biomanufacturing facility that will catalyze Ontario life sciences jobs and innovation while advancing pioneering medicine with the potential to cure, not just treat, many forms of cancer, cardiovascular diseases, Parkinson's and diabetes. OmniaBio, a Canadian cell and gene therapy contract development and manufacturing organization (CDMO), will be the anchor tenant in a new biomanufacturing campus being built in Ha...

Read More

MEDICAL

DUKE RESEARCHERS IDENTIFY GENETIC MECHANISM IN BRAIN LESION FORMATION USING SINGLE-CELL DNA SEQUENCING FROM MISSION BIO

Mission Bio | March 15, 2022

news image

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced new findings by Daniel Snellings from the lab of Douglas Marchuk, PhD, at Duke University School of Medicine using single-cell DNA sequencing to identify genetic mechanisms leading to the development of cerebral cavernous malformations (CCMs). The study, published today in the journal Nature Cardiovascular Research, is the latest demonstration of how Mission Bio's Tapestri Platform is allowing res...

Read More

INDUSTRIAL IMPACT

VERSANT VENTURES COLLABORATES WITH ABCELLERA TO ACCELERATE DRUG DEVELOPMENT FOR ITS PORTFOLIO OF BIOTECH COMPANIES

AbCellera and Versant Ventures | July 28, 2022

news image

AbCellera and Versant Ventures announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs. Versant and AbCellera already have enabled three of the firm’s stealth-stage companies under previous partnerships. Under the terms of the deal, Versant portfolio companies will have rights to develop and commercialize the resulting therapeutic antibodies. AbCellera will receive resear...

Read More
news image

AKERS BIOSCIENCES AND PREMAS BIOTECH ANNOUNCE PROGRESS IN ITS VACCINE DEVELOPMENT FOR COVID-19

PipelineReview | April 06, 2020

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate. The clone development process has four primary steps including first, the design and synthesis of the genes; second, the selecti...

Read More
news image

MEDICAL

INVEST ONTARIO SUPPORTS NEW BIOMANUFACTURING FACILITY IN HAMILTON

Invest Ontario | April 01, 2022

Invest Ontario is supporting OmniaBio Inc. in launching a new biomanufacturing facility that will catalyze Ontario life sciences jobs and innovation while advancing pioneering medicine with the potential to cure, not just treat, many forms of cancer, cardiovascular diseases, Parkinson's and diabetes. OmniaBio, a Canadian cell and gene therapy contract development and manufacturing organization (CDMO), will be the anchor tenant in a new biomanufacturing campus being built in Ha...

Read More
news image

MEDICAL

DUKE RESEARCHERS IDENTIFY GENETIC MECHANISM IN BRAIN LESION FORMATION USING SINGLE-CELL DNA SEQUENCING FROM MISSION BIO

Mission Bio | March 15, 2022

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced new findings by Daniel Snellings from the lab of Douglas Marchuk, PhD, at Duke University School of Medicine using single-cell DNA sequencing to identify genetic mechanisms leading to the development of cerebral cavernous malformations (CCMs). The study, published today in the journal Nature Cardiovascular Research, is the latest demonstration of how Mission Bio's Tapestri Platform is allowing res...

Read More
news image

INDUSTRIAL IMPACT

VERSANT VENTURES COLLABORATES WITH ABCELLERA TO ACCELERATE DRUG DEVELOPMENT FOR ITS PORTFOLIO OF BIOTECH COMPANIES

AbCellera and Versant Ventures | July 28, 2022

AbCellera and Versant Ventures announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs. Versant and AbCellera already have enabled three of the firm’s stealth-stage companies under previous partnerships. Under the terms of the deal, Versant portfolio companies will have rights to develop and commercialize the resulting therapeutic antibodies. AbCellera will receive resear...

Read More